Scientists track Long-Term fate of melanoma patients after experimental treatment
NCT ID NCT06848088
Summary
This study is tracking the long-term health of 48 people with advanced skin cancer (melanoma) who previously received an experimental two-drug combination. No new treatment is given during this follow-up phase. Researchers are monitoring cancer status, overall health, and any additional treatments patients have received to understand the lasting effects of the earlier therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Pacific Medical Center
San Francisco, California, 94115, United States
-
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49546, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Oncology And Hematology
San Antonio, Texas, 78229, United States
-
St. Vincent's University Hospital
Dublin, D04 T6F4, Ireland
-
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, 90025, United States
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.